Bliss GVS Pharma Limited has informed the Exchange regarding ‘Intimation under Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Grant of Marketing Authorisation from MHRA, UK for Mesalazine 1g Suppositories’|SUBJECT: Updates
Source link
Revolutionary taking place